A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal on the Bioavailability of a 40 mg Extended-Release (XR) Deucrictibant Oral Formulation Administered as a Single Dose.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518453-41-00

Acronym

PHA022121-C021

Enrollment

Registered

2024-11-15

Start date

2024-12-30

Completion date

2025-02-19

Last updated

2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary angioedema (HAE)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Hungary

None listed

Source: EU CTIS · Data processed: Feb 4, 2026